- Health Spotlight's Mantle Cell Lymphoma Insights
- Posts
- Weekly Spotlight - 19.12.24
Weekly Spotlight - 19.12.24
Promising New Treatment for Elderly Mantle Cell Lymphoma Patients Shows Success
Liam Ball
December 19, 2024
Community |
Your journey can be a beacon of hope and a source of strength for others in our community. Together, we can build a stronger, more supportive community. Your story matters, and it deserves to be heard. Fill in this form to be featured. |
Latest News
Promising New Treatment for Elderly Mantle Cell Lymphoma Patients Shows Success
The study explored a treatment for elderly mantle cell lymphoma patients using bortezomib, cladribine, and rituximab. Results were promising, with high response and remission rates. The treatment was well-tolerated, showing minimal toxicity. Potential biomarkers were identified, offering hope for effective, low-toxicity therapy in older patients.
Bone marrow assessment is crucial in evaluating mantle cell lymphoma. PET/CT scans offer significant prognostic value, especially when combined with biopsies. This study proposes a new model, MCL-PET-I, to better predict patient outcomes, highlighting the importance of these assessments in treatment planning.
Glofitamab shows promise in treating mantle cell lymphoma, achieving high response rates and durable remissions. Patients experienced significant improvements, with many achieving complete remission. Despite some adverse effects, the treatment benefits are encouraging, offering hope to those with relapsed or refractory conditions. The study highlights potential for future lymphoma therapies.
The study highlights the Lawton iADL scale effectiveness in predicting treatment outcomes for elderly lymphoma patients. It shows that this tool can foresee treatment response and survival rates, offering hope for better patient care. The scale is simple, quick, and universally applicable in geriatric assessments.
=
Health Spotlight’s Mantle Cell Lymphoma is a Contentive publication in the Healthcare division